Page last updated: 2024-11-12
gymnemagenin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
gymnemagenin: isolated from Gymnema sylvestre [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Gymnema | genus | A plant genus of the family ASCLEPIADACEAE.[MeSH] | Apocynaceae | The dogbane family of the order Gentianales. Members of the family have milky, often poisonous juice, smooth-margined leaves, and flowers in clusters.[MeSH] |
| Gymnema sylvestre | species | A plant species of the genus GYMNEMA that contains gymnemic acid (triterpene SAPONINS) which affects blood sugar level, and gurmarin protein. The common name of Gurmar should not be confused with Guar (CYAMOPSIS).[MeSH] | Apocynaceae | The dogbane family of the order Gentianales. Members of the family have milky, often poisonous juice, smooth-margined leaves, and flowers in clusters.[MeSH] |
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 10051937 |
| SCHEMBL ID | 4324523 |
| MeSH ID | M0507699 |
Synonyms (23)
| Synonym |
|---|
| SCHEMBL4324523 |
| 22467-07-8 |
| gymnemagenin |
| olean-12-ene-3,16,21,22,23,28-hexol, (3.beta.,4.alpha.,16.beta.,21.beta.,22.alpha.)- |
| gymnemagenin [usp-rs] |
| olean-12-ene-3.beta.,16.beta.,21.beta.,22.alpha.,23,28-hexo |
| U396WHT2FZ , |
| gymnemagenin (constituent of gymnema) [dsc] |
| unii-u396wht2fz |
| olean-12-ene-3beta,16beta,21beta,22alpha,23,28-hexol |
| gymnemagenin, united states pharmacopeia (usp) reference standard |
| gymnemagenin, analytical standard |
| AKOS037515112 |
| (3r,4r,4ar,5s,6ar,6as,6br,8ar,9r,10s,12ar,14bs)-4a,9-bis(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-3,4,5,10-tetrol |
| HY-N2268 |
| CS-0019597 |
| Q27290632 |
| AS-79649 |
| gymnemagenin (usp-rs) |
| gymnemagenin (constituent of gymnema) |
| olean-12-ene-3beta,16beta,21beta,22alpha,23,28-hexo |
| olean-12-ene-3,16,21,22,23,28-hexol, (3beta,16beta,21beta,22alpha)- |
| olean-12-ene-3,16,21,22,23,28-hexol, (3beta,4alpha,16beta,21beta,22alpha)- |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " In present investigation, pharmacodynamics and pharmacokinetic interactions with oral hypoglycemic drug, glimepiride (GLM) was studied in streptozotocin (STZ) induced diabetic rats." | ( Effects of Gymnema sylvestre extract on the pharmacokinetics and pharmacodynamics of glimepiride in streptozotocin induced diabetic rats. Duraiswamy, B; Gupta, A; Jadhav, A; Janrao, S; Kamble, B; Khatal, L; Moothedath, I, 2016) | 0.43 |
| " Therefore, the objective of our study was to investigate the in vitro rat liver microsomal stability and caco-2 permeability along with the efflux of gymnemagenin and establish a probable correlation of these in vitro findings with pharmacokinetic parameters after oral and intravenous administration in rats." | ( In Vitro Metabolic Stability and Permeability of Gymnemagenin and Its In Vivo Pharmacokinetic Correlation in Rats - A Pilot Study. Adhikari, D; Bera, R; Karmakar, S; Kundu, A; Sen, T, 2016) | 0.89 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (9)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 25.09
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.09) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||